---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-199425"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:36.776602+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# UroGen ahead of schedule completing UGN-102 NDA; Q2 revenue $21.8M, net loss $33.4M

## Summary
- UGN-102 NDA completion imminent; potential FDA decision as early as Q1 2025 assuming priority review.
- Q2 JELMYTO net revenue $21.8M (+3% YoY); full-year revenue expected at lower end of guidance range.
- Q2 net loss $33.4M ($0.91/share) vs $24.1M ($1.03/share) in Q2 2023; operating loss $25.8M.
- Cash & marketable securities $241.3M at June 30; June public offering raised $107.5M gross.
- Full-year operating expenses expected at higher end of guidance; R&D $15.4M, SG&A $30.1M in Q2.

## SEC filing metadata
- accession: 0001193125-24-199425
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524199425/0001193125-24-199425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524199425/d865545d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-199425
- JSON: https://secwatch.observer/filing/0001193125-24-199425.json
- Plain text: https://secwatch.observer/filing/0001193125-24-199425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.